Browsing by Subject "Cancer cell"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    ItemOpen Access
    A new tool for differentiating hepatocellular cancer cells: patterned carbon nanotube arrays
    (Elsevier, 2015) Kucukayan-Dogu, G.; Gozen, D.; Bitirim, V.; Akcali, K. C.; Bengu, E.
    We aimed to develop a new approach to detect the invasiveness and metastatic degree of hepatocellular carcinoma cells (HCC) based on their epithelial mesenchymal transition (EMT) status by using patterned carbon nanotubes (CNT) without any further surface functionalization. We used well differentiated HUH7 and poorly differentiated SNU182 cells to examine and compare their adhesive features on patterned CNTs. We found that the well differentiated HUH7 cells attached significantly more on the patterned CNTs than the poorly differentiated SNU182 cells due to the difference in epithelial and mesenchymal phenotypes of these cells. Collagen coated patterned CNTs having less roughness resulted in a decrease in the number of attached cells compared to non-coated patterned surfaces indicating that surface topography playing also a vital role on the cell attachment. LDH testing indicated no adverse, or thereof toxic effect of collagen coated or non-coated patterned surfaces on the HCC cells. The results of this study clearly suggest that patterned CNT surfaces can be used as a diagnostic tool to determine the invasiveness and metastatic level of HCCs. Hence, CNTs could be considered as a promising diagnostic tool for the detection of differentiation and invasiveness of the HCC cells. © 2015 Elsevier B.V. All rights reserved.
  • Thumbnail Image
    ItemOpen Access
    Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells
    (Royal Society of Chemistry, 2017) Kahraman, D. C.; Hanquet, G.; Jeanmart, L.; Lanners, S.; Šramel, P.; Boháč, A.; Cetin-Atalay, R.
    Bioactivities of quinoides 1–5 and VEGFR2 TKIs 6–10 in hepatocellular cancer (HCC) and cancer stem cells (HCSCs) were studied. The compounds exhibited IC50 values in μM concentrations in HCC cells. Quinoide 3 was able to eradicate cancer stem cells, similar to the action of the stem cell inhibitor DAPT. However, the more cytotoxic VEFGR TKIs (IC50: 0.4–3.0 μM) including sorafenib, which is the only FDA approved drug for the treatment of HCC, enriched the hepatocellular cancer stem cell population by 2–3 fold after treatment. An aggressiveness factor (AF) was proposed to quantify the characteristics of drug candidates for their ability to eradicate the CSC subpopulation. Considering the tumour heterogeneity and marker positive cancer stem cell like subpopulation enrichment upon treatments in patients, this study emphasises the importance of the chemotherapeutic agent choice acting differentially on all the subpopulations including marker-positive CSCs.